U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details

Ribociclib

Last Revision: December 3, 2018.

CASRN: 1211441-98-3

Chemical structure

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of ribociclib during breastfeeding. Because protein binding of ribociclib is 70%, clinically important amounts of the drug might pass into breastmilk. The manufacturer recommends that breastfeeding be discontinued during ribociclib therapy and for at least 3 weeks after the final dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Ribociclib

CAS Registry Number

1211441-98-3

Drug Class

  • Breast Feeding
  • Lactation
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Protein Kinase Inhibitors
  • Signal Transduction Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK500944PMID: 30000003

Views

Related information

Similar articles in PubMed

  • Review Binimetinib.[Drugs and Lactation Database (...]
    Review Binimetinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Osimertinib.[Drugs and Lactation Database (...]
    Review Osimertinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Acalabrutinib.[Drugs and Lactation Database (...]
    Review Acalabrutinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Glasdegib.[Drugs and Lactation Database (...]
    Review Glasdegib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.[Ann Pharmacother. 2019]
    Review Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
    Rascon K, Flajc G, De Angelis C, Liu X, Trivedi MV, Ekinci E. Ann Pharmacother. 2019 May; 53(5):501-509. Epub 2018 Dec 7.
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...